19 Sep 2007 - bioMérieux and Ipsen announced that they have signed an agreement by which bioMérieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen. The development will be co-funded by bioMérieux and Ipsen.
Ipsen is developing a novel breast cancer therapy, BN 83495, targeting the steroid sulfatase enzyme (STS). The new drug, designed to block this marker found in hormone-dependent breast cancer in postmenopausal women, is currently in phase I clinical development.
bioMérieux will devise a companion assay to determine the patients best suited to benefit from the new STS inhibitor treatment. The assay is intended for both the clinical development of the Ipsen drug as well as a diagnostic test, potentially for future commercialization. The test will be developed on bioMérieux's NucliSENS EasyQ® molecular diagnostics platform, using the company's proprietary NASBA® amplification technology.
 |
www.bionity.com/news/e/69805 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/69805 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |